Lyra Therapeutics Stock Surges On Equity Raise Of $100M

Loading...
Loading...
  • Lyra Therapeutics Inc LYRA has announced a private placement of approximately $100.5 million.
  • The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share, at $4.219 per share.
  • Each pre-funded warrant will be exercisable immediately. 
  • Related: Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients.
  • The offering will close by April 12.
  • LYR-210 and LYR-220 are designed to be administered in non-invasive, in-office procedures and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages of CRS patients.
  • As of December 31, 2021, cash & cash equivalents were $45.7 million.
  • Price Action: LYRA shares are up 26.2% at $5.45 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...